Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization

References

• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639. DOI:10.1161/CIR.0000000000001052
   PubMed Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5(15):1–6.
   Google Scholar
• Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015;175(6):996–1004. DOI:10.1001/jamainternmed.2015.0924
   PubMed Web of Science ®Google Scholar
• Escobar C, Palacios B, Varela L, et al. Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection Fraction in Spain. J Clin Med. 2022;11(17):5199. DOI:10.3390/jcm11175199. .
   PubMedGoogle Scholar
• McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. DOI:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Anguita Gámez M, Esteban Fernández A, García Márquez M, et al. Age and stabilization of admissions for heart failure in Spain (2006-2019). The beginning of the end of the “epidemic”? Rev Esp Cardiol (Engl Ed). 2022 Oct 10. Epub ahead of print. DOI:10.1016/j.rec.2022.08.009
   Google Scholar
• Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–944. DOI:10.1016/j.jacc.2018.11.049.
   PubMed Web of Science ®Google Scholar
• Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11.
   PubMedGoogle Scholar
• O´connor C, Miller AB, Blair JE, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptam (EVEREST) program. Am Heart J. 2010;159(5):841–849. DOI:10.1016/j.ahj.2010.02.023
   PubMedGoogle Scholar
• Gracia E, Singh P, Collins S, et al. The vulnerable phase of heart failure. Am J Ther. 2018;25(4):e456–464.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Vitale C, Adamo M, et al. Roadmap for the management of heart failure patients during the vulnerable phase after heart failure hospitalizations: how to implement excellence in clinical practice. J Cardiovasc Med (Hagerstown). 2022;23(3):149–156.
   PubMedGoogle Scholar
• Greene SJ, Butler J, Fonarow GC. In-hospital Initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. Eur J Heart Fail. 2022;24(1):227–229.
   PubMedGoogle Scholar
• Latif A, Lateef N, Lundgren S, et al. Vulnerable phase of acute heart failure and its association with hospital readmissions reduction program. Curr Probl Cardiol. 2022;47(5):100904.
   PubMedGoogle Scholar
• Rizzi MA, Sarasola AG, Arbé AA, et al. Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study. Clin Res Cardiol. 2021;110(7):993–1005. DOI:10.1007/s00392-020-01710-0.
   PubMedGoogle Scholar
• Çavuşoğlu Y, Altay H, Nalbantgil S, et al. Pre-discharge and post-discharge management and treatment optimization in acute heart failure. Turk Kardiyol Dern Ars. 2022;50(5):378–394.
   PubMedGoogle Scholar
• Arrigo M, Jessup M, Mullens W, et al. Acute Heart Failure. Nat Rev Dis Primers 6(1), p. 16 (2020).
   Google Scholar
• Januzzi JL Jr, Butler J. The importance of worsening heart failure: hiding in plain sight. J Am Coll Cardiol. 2022;80(2):123–125.
   PubMed Web of Science ®Google Scholar
• Antoine S, Vaidya G, Imam H, et al. Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. Am J Med Sci. 2017;353(1):27–30.
   PubMed Web of Science ®Google Scholar
• Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21–32.
   PubMed Web of Science ®Google Scholar
• Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342–1347.
   PubMed Web of Science ®Google Scholar
• Sandner P, Follmann M, Becker-Pelster E, et al. Soluble GC stimulators and activators: past, present and future. Br J Pharmacol Oct. 2021;2. Epub ahead of print. DOI:10.1111/bph.15698
   Google Scholar
• Nightingale B. A review of the proposed mechanistic actions of sodium glucose cotransporter-2 inhibitors in the treatment of heart failure. Cardiol Res. 2021;12(2):60–66.
   PubMed Web of Science ®Google Scholar
• Severino P, D’amato A, Prosperi S, et al. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Fail Rev. 2021 Oct 16; Epub ahead of print. DOI:10.1007/s10741-021-10170-1.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121–128. DOI:10.1016/S0140-6736(20)30748-0.
   PubMed Web of Science ®Google Scholar
• Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10(2):73–84.
   PubMedGoogle Scholar
• Aimo A, Pateras K, Stamatelopoulos K, et al. Relative efficacy of sacubitril-valsartan, vericiguat, and sglt2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021;35(5):1067–1076.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? a redefinition of evidence-based medicine. Circulation. 2021;143(9):875–877.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Docherty KF. Insights into foundational therapies for heart failure with reduced ejection fraction. Clin Cardiol. 2022;45(Suppl 1):S26–30.
   PubMedGoogle Scholar
• Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209–216.
   PubMed Web of Science ®Google Scholar
• Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J. 2014;168(5):721–730.
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(6A):11G–17G.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Anker SD, Cleland JGF, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 2014;1(2):110–145.
   PubMedGoogle Scholar
• Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3(3):252–259.
   PubMedGoogle Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
   PubMed Web of Science ®Google Scholar
• He Y, Lu X, Zheng Y, et al. Efficacy and safety of sacubitril/valsartan therapy for acute decompensated heart failure with reduced ejection fraction during the vulnerable phase: a multicenter, assessor-blinded, prospective, observational, cohort study. Cardiol. 2021;146(3):335–344.
   PubMedGoogle Scholar
• Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998–1007.
   PubMed Web of Science ®Google Scholar
• Gattis WA, O’connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43(9):1534–1541.
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190–199.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–1321.
   PubMed Web of Science ®Google Scholar
• Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol. 2014;114(5):737–742.
   PubMed Web of Science ®Google Scholar
• Bistola V, Simitsis P, Farmakis D, et al. Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol. 2018;107(1):76–86.
   PubMed Web of Science ®Google Scholar
• Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950–958.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893.
   PubMed Web of Science ®Google Scholar
• Greene SJ, Butler J, Fonarow GC. Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed. JAMA Cardiol. 2021;6(7):743–744.
   PubMed Web of Science ®Google Scholar
• Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during Ihospitalization. JACC Heart Fail. 2019;7(1):1–12.
   PubMed Web of Science ®Google Scholar
• Cox ZL, Nandkeolyar S, Johnson AJ, et al. In-hospital initiation and up-titration of guideline-directed medical therapies for heart failure with reduced ejection fraction. Card Fail Rev. 2022;8:e21.
   PubMedGoogle Scholar
• Driscoll A, Dinh D, Prior D, et al. The effect of transitional care on 30-day outcomes in patients hospitalised with acute heart failure. Heart Lung Circ. 2020;29(9):1347–1355.
   PubMed Web of Science ®Google Scholar
• Nair N, Ray N, Pachariyanon P, et al. Impact of Outpatient Diuretic Infusion Therapy on Healthcare Cost and Readmissions. Int J Heart Fail. 2022;4(1):29–41.
   PubMedGoogle Scholar
• Verma V, Zhang M, Bell M, et al. Outpatient intravenous diuretic clinic: an effective strategy for management of volume overload and reducing immediate hospital admissions. J Clin Med Res. 2021;13(4):245–251.
   PubMedGoogle Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Okumura N, Jhund PS, Gong J, et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016;133(23):2254–2262.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6(6):706–712.
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Enjuanes C, Lupón J, et al. Transitions of care between acute and chronic heart failure: critical steps in the design of a multidisciplinary care model for the prevention of rehospitalization. Rev Esp Cardiol (Engl Ed). 2016;69(10):951–961.
   PubMedGoogle Scholar
• Skali H, Dwyer EM, Goldstein R, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: mADIT-CRT. Eur J Heart Fail. 2014;16(5):560–565.
   PubMedGoogle Scholar
• Cox ZL, Stevenson LW. The weight of evidence for diuretics and parachutes. J Am Coll Cardiol. 2020;76(6):680–683.
   PubMedGoogle Scholar
• Okumura N, Jhund PS, Gong J, et al. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ Heart Fail. 2016;9(9):e003212.
   PubMed Web of Science ®Google Scholar
• Khan MS, Greene SJ, Hellkamp AS, et al. Diuretic changes, health care resource utilization, and clinical outcomes for heart failure with reduced ejection fraction: from the change the management of patients with heart failure registry. Circ Heart Fail. 2021;14(11):e008351.
   PubMedGoogle Scholar
• Sargento L, Simões AV, Longo S, et al. Furosemide prescription during the dry state is a predictor of long-term survival of stable, optimally medicated patients with systolic heart failure. J Cardiovasc Pharmacol Ther. 2017;22(3):256–263.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349–1355.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–2107.
   PubMed Web of Science ®Google Scholar
• Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–2626.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• Muntwyler J, Abetel G, Gruner C, et al. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23(23):1861–1866.
   PubMed Web of Science ®Google Scholar
• Escobar C, Palacios B, Varela L, et al. Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain. BMC Health Serv Res. 2022;22(1):1241.
   PubMedGoogle Scholar
• Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, et al. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. Rev Esp Cardiol (Engl Ed). 2021;74(6):533–543.
   PubMedGoogle Scholar
• Krantz MJ, Ambardekar AV, Kaltenbach L, et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get with the GuidelinesHeart Failure). Am J Cardiol. 2011;107(12):1818–1823.
   PubMed Web of Science ®Google Scholar
• Biegus J, Moayedi Y, Saldarriaga C, et al. Getting ahead of the game: in-hospital initiation of HFrEF therapies. Eur Heart J Suppl. 2022;24(Suppl L):L38–44.
   PubMedGoogle Scholar
• Scicchitano P, Iacoviello M, Massari F, et al. Optimizing therapies in heart failure: the role of potassium binders. Biomedicines. 2022;10(7):1721.
   PubMedGoogle Scholar
• Delanaye P, Scheen AJ. The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021;47(6):101285.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Ménard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58(19):1958–1966.
   PubMed Web of Science ®Google Scholar
• Gronda E, Vanoli E, Sacchi S, et al. Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options. Heart Fail Rev. 2020;25(2):295–303.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Ortiz Cortés C, et al. Management of patients with heart failure treated in cardiology consultations: iC-BERG Study. Rev Clin Esp (Barc). 2020;220(6):339–349.
   PubMedGoogle Scholar
• Escobar C, Barrios V, Cortés CO, et al. Recommendations to improve the management and the prognosis of patients with heart failure. Future Cardiol. 2020;16(1):1–4.
   PubMedGoogle Scholar